Related Experiment Video
Updated: May 27, 2025

03:22
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
15.0K
GLP-1 Agonists in Patients with Hidradenitis Suppurativa: A Case Series
Melissa M Rames1, Afsaneh Alavi1, Nessa Aghazadeh1
1Mayo Clinic Department of Dermatology, Rochester, MN, USA.
Journal of Cutaneous Medicine and Surgery
|February 18, 2025
Abstract
No abstract available in PubMed .
Related Concept Videos
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164

